Medpace Holdings Inc (NASDAQ:MEDP) reported fourth-quarter financial results after the market close on Monday. Here’s a rundown of the report.
Total revenue was up 7.7% on a year-over-year basis. New business awards totaled $529.7 million in the quarter, down 13.8% year-over-year. The company ended the period with a backlog of approximately $2.9 billion, up 3.2% year-over-year.
Medpace generated $190.7 million in cash flow from operations during the quarter. The company had cash and cash equivalents of $669.4 million as of Dec. 31.
Medpace said it repurchased $174.2 million of its common stock during the quarter. The company had $134.6 million remaining under its buyback at quarter’s end. Additionally, Medpace’s board approved an increase of $600 million to the company’s buyback program on Feb. 6.
Check This Out: Lattice Semiconductor Shares Jump After Mixed Q4 Results, Strong Q1 Guidance
Outlook: Medpace expects full-year 2025 revenue to be in the range of $2.11 billion to $2.21 billion. The company sees full-year earnings in the range of $11.93 per share to $12.69 per share.
Medpace executives will further discuss the quarter on a call with investors and analysts at 9 a.m. ET Tuesday morning.
MEDP Price Action: At publication time Monday, Medpace shares were down 8.33% at $324.97 in after-hours trading, according to Benzinga Pro.
Photo: Shutterstock.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.